Group 1 - The sixth National Excellent Builders of Socialism with Chinese Characteristics award ceremony was held, recognizing 100 individuals, including Liang Yaoming, CEO of KingMed Diagnostics [1] - The award is jointly evaluated by several government departments and honors non-public economic individuals for their patriotism, law-abiding business practices, innovation, and social contributions [1] - Liang Yaoming expressed commitment to advancing the integration of biotechnology and new information technology to enhance diagnostic capabilities and contribute to the "Healthy China" initiative [1] Group 2 - KingMed Diagnostics pioneered the third-party medical testing industry in the 1990s, providing diagnostic services to various medical institutions [2] - The company has established a comprehensive service system that innovates diagnostic technologies and enhances clinical capabilities for rare and complex diseases [2] - KingMed Diagnostics has become a leading third-party medical testing institution in China, covering over 90% of the population and collaborating with more than 23,000 medical institutions nationwide [2]

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 600500 | 中化国 际 | 10.10 | 1.97 | 3.92 | 4.25 | 8.45 | | 300776 | 帝尔激 光 | 4.31 | 3.58 | 58.61 | 60.98 | 4.04 | | 301348 | 蓝箭电 子 | 2.94 | 11.13 | 21.10 | 21.68 | 2.76 | | 688007 | 光峰科 技 | 3.97 | 2.92 | 15.32 | 15.72 | 2.62 | | 603806 | 福斯特 | 10.04 | 4.59 | 14.34 | 14.69 | 2.44 | | 000560 | 我爱我 家 | 2.56 | 11.01 | 3.13 | 3.21 | 2.39 | | 6 ...

Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index at 3595.19 points, remaining above the annual line, indicating mixed investor sentiment in the market [1] Group 1: Market Performance - The A-share total trading volume reached 1,145.862 billion yuan today [1] - The Shanghai Composite Index experienced a change of -0.08% [1] Group 2: Stocks Breaking Annual Line - A total of 11 A-shares have surpassed the annual line today, with notable stocks including Sinochem International, Blue Arrow Electronics, and I Love My Home, showing significant deviation rates of 8.45%, 2.76%, and 2.71% respectively [1] - Other stocks like Wanli Stone, CITIC Offshore, and Puri Eye Hospital have just crossed the annual line with smaller deviation rates [1] Group 3: Stock Deviation Rate Rankings - The top three stocks with the highest deviation rates are: 1. Sinochem International (10.10% increase, deviation rate 8.45%) 2. Blue Arrow Electronics (2.94% increase, deviation rate 2.76%) 3. I Love My Home (2.88% increase, deviation rate 2.71%) [1] - Additional stocks with notable performance include: - Empire Laser (2.60% increase, deviation rate 2.34%) - Guangfeng Technology (3.31% increase, deviation rate 1.97%) [1]

7月28日早盘，制药板块走强，化学药、生物药、中药等三大纯制药领域龙头股齐涨，国内首只的药 ETF（562050）盘初冲击2%。成份股海思科涨停，巨头恒瑞医药涨超6%；太极集团、以岭药业等中药 龙头涨超2%。 把握中国龙头药企价值重估机遇，配置工具关注国内首只药ETF（562050）。聚焦A股50大龙头药企， 重仓创新药，兼顾中药，且完全不含医疗和CXO。 同时看好医疗器械、CXO，可以关注A股最大医疗ETF（512170）。聚焦"医疗器械+医疗服务"，与AI 医疗高相关，覆盖6只CXO龙头股。场外联接基金（A类 162412 / C类 012323）。 风险提示：医疗ETF及其联接基金被动跟踪中证医疗指数，该指数基日为2004.12.31，发布于 2014.10.31。药ETF被动跟踪中证制药指数，该指数基日为2011.12.30，发布日期为2013.7.15，2020- 2024年分年度历史收益分别为：41.61%、-9.10%、-21.09%、-3.70%、-6.53% ，指数成份股构成根据该 指数编制规则适时调整，其回测历史业绩不预示指数未来表现。文中指数成份股仅作展示，个股描述不 作为任何形式的投资 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Summary of Key Points from the Conference Call Industry Overview - **Industry Focus**: The conference call primarily discusses the healthcare sector in China, particularly the medical technology (Medtech), in vitro diagnostics (IVD), retail pharmacies, hospitals, vaccines, and insulin markets [1][2]. Core Insights and Arguments Medtech - **Key Areas of Focus**: 1. Progress of capital equipment value-based procurement (VBP) and the trade-in policy [1] 2. Channel destocking trends [1] 3. Import substitution trends post-VBP, including intraocular lenses (IOLs) and IVD [1] - **VBP Impact**: The June bidding value data showed a year-on-year growth rate of 49%, but a month-on-month decline of 3%, indicating lower unit prices due to VBP [10]. IVD Market - **Weak Demand**: The IVD sector continues to face challenges, with a projected 20% year-on-year decline in the CLIA reagent market size for 2025 [19]. - **AmoyDx Performance**: AmoyDx is expected to grow against the trend due to its strong presence in compliant in-hospital sales channels, benefiting from the anti-corruption campaign [21]. Insulin Market - **Domestic Substitution**: The insulin industry has seen significant growth, particularly for insulin analogs from companies like Gan & Lee and THDB, which reported rapid revenue growth in 1Q25 [22]. Retail Pharmacies - **Market Pressure**: Retail pharmacies are under pressure due to strict reimbursement policies and weak consumer spending. However, there is a potential market-clearing trend expected by year-end [31]. Hospitals - **New Product Feedback**: Hospitals are seeing new product introductions, such as the new version of SMILE surgery and new PIOL products, which are expected to drive consumption recovery [1]. Vaccine Market - **Anti-Corruption Campaign**: The ongoing anti-corruption campaign within the CDC system is impacting vaccine demand and distribution channels [1]. Financial Performance and Estimates Earnings Revisions - **Mindray**: Annual earnings estimates revised down by 2.1% to 5.0% for 2025E-27E due to industry headwinds in medical equipment and IVD [2][37]. - **United Imaging**: Revenue and earnings forecasts adjusted down to reflect lower-than-expected bidding data [39]. - **SNIBE**: Earnings estimates revised down by 1.4% to 7.1% for 2025E-27E due to policy headwinds in the IVD sector [40]. Revenue Growth Expectations - **High Growth Companies**: THDB and Gan & Lee are expected to achieve the highest revenue growth due to a low base from VBP renewal in 2Q24 [6]. - **Mindray's Decline**: Mindray's China business is expected to decline by 26% year-on-year in 2Q25 due to IVD weakness [9]. Other Important Insights - **Trade-in Policy Concerns**: The trade-in stimulus fund is expected to run out, leading to a decline in applications and a reduced stimulus effect in the second half of 2025 [10]. - **Market Dynamics**: The healthcare market is experiencing a shift with increasing government support for procurement and a focus on innovative products [47][48]. Conclusion - The healthcare sector in China is facing various challenges, including policy headwinds, weak demand in certain segments, and the impact of ongoing reforms. However, there are also opportunities for growth, particularly in innovative products and domestic substitution trends. Companies like AmoyDx, Gan & Lee, and THDB are positioned to benefit from these trends, while others like Mindray and SNIBE are facing headwinds that may impact their performance in the near term.

Core Viewpoint - The epidemic of Chikungunya fever in Guangdong Province remains at a high plateau, indicating a severe situation that requires attention [1]. Summary by Sections Epidemic Situation - As of July 22, 2025, Shunde District in Foshan City reported a total of 2,934 confirmed cases of Chikungunya fever, with a significant increase of 463 cases in just one day [4][5]. - The first report of the epidemic in Shunde was on July 15, 2025, with 478 confirmed cases, showing an increase of over 2,000 cases in just over a week [4]. - The World Health Organization (WHO) reported that 119 countries and regions have identified Chikungunya virus transmission, with approximately 5.5 million people at risk globally, potentially leading to widespread outbreaks [4][5]. Companies Involved in Prevention and Detection - **Runben Co., Ltd. (润本股份)**: A leading domestic company in mosquito repellent products, with a revenue of 440 million yuan in 2024, showing a year-on-year growth of 35.4% and a gross margin of 54.2% [7]. - **Rainbow Group (彩虹集团)**: A well-known pest control company in China, offering a full range of mosquito repellent products that play a crucial role in controlling Chikungunya fever [8]. - **Shanghai Jahwa (上海家化)**: The "Liushen" brand is the top brand in China for mosquito repellent flower water, holding significant brand influence in mosquito prevention and personal care [9]. - **Longyun Group (朗云集团)**: A Hong Kong-listed company that has maintained the number one market share in pest control products for ten consecutive years, with notable products performing well during the epidemic [10]. - **Kangzhi Pharmaceutical (康芝药业)**: Offers a full range of baby and child health protection products, including disinfectants and mosquito repellents, demonstrating expertise in child health protection [11]. - **Shuoshi Gene (硕世纪录物)**: Utilizes gene sequencing technology for Chikungunya fever testing, providing precise diagnostic support for epidemic prevention [12]. - **Da'an Gene (达安基因)**: Provides nucleic acid testing kits for Chikungunya virus, leveraging extensive experience in molecular diagnostics [13]. - **Huiyu Medical (会域医学)**: A leading medical testing institution in China, employing advanced technology for accurate diagnosis of Chikungunya fever [14]. - **Wansheng Biology (万学生物)**: Offers rapid testing solutions for Chikungunya virus, focusing on point-of-care testing [16]. - **Nuo Weisha (诺唯莎)**: Combines molecular design with various heat-start technologies to enhance detection efficiency for mosquito-borne viruses [17].

Group 1 - The number of confirmed cases of Chikungunya fever in Shunde, Guangdong has reached 2,934, primarily affecting Lecong, Beijiao, and Chen Village, all of which are mild cases [1][2] - The World Health Organization has issued a warning regarding the potential for widespread outbreaks of Chikungunya fever, with 119 countries and regions reporting cases, putting approximately 5.5 million people at risk [2][3] - Local governments in Guangdong are actively promoting mosquito control measures, including public announcements urging citizens to eliminate mosquito breeding sites and participate in coordinated mosquito eradication efforts [2][3] Group 2 - The "mosquito repellent concept" has gained traction in the capital markets, with stocks related to mosquito control and testing reagents seeing significant increases [5][6] - Companies such as Rainbow Group and Kangzhi Pharmaceutical have experienced stock price surges, while others like Runben Co., Shanghai Jahwa, and Qingsong Co. have also seen gains [6] - Several companies, including Rendu Biotech and Mindray, have highlighted their mosquito-borne virus testing products, indicating a growing market interest in diagnostic tools for diseases like Chikungunya [6]

Core Viewpoint - The inclusion of Guangzhou Kingmed Diagnostics Group Co., Ltd. in the first batch of trusted data space innovation development pilot projects signifies national recognition of its practices in medical data security and application, addressing the challenges of data sharing in the healthcare industry [1][2]. Group 1: Company Overview - Kingmed Diagnostics has over 30 years of experience in the medical testing industry, possessing a core asset of more than 3 billion medical testing data and a service network covering over 90% of the Chinese population [2]. - The company serves more than 23,000 medical institutions, positioning itself as a pioneer in the marketization of medical data elements [2]. Group 2: Industry Impact - The pilot project aims to break the long-standing data isolation issues in the medical industry, enhancing the value of data as a production factor and promoting compliant circulation of medical data [2]. - The trusted data space is viewed as a "data safe house," allowing different data providers to share data securely, which is crucial for the healthcare sector [1][2]. Group 3: Future Strategy - Kingmed Diagnostics plans to leverage the trusted data space as a key infrastructure for its "data + AI" strategy, aiming to create a second growth curve driven by data elements [2]. - The company intends to enhance the platform attributes and public service functions of the data space over the next five years, attracting more hospitals, doctors, and individuals to participate [2].

Group 1 - The core point of the article is that Kingmed Diagnostics, a leading medical testing company in A-shares, is expected to report a net loss of between 95 million to 65 million yuan in the first half of 2025, marking its first semi-annual loss since its listing [1] - The company attributes its losses to economic cycles and macro policy environments impacting short-term business development, as well as proactive optimization of customer structure leading to lower-than-expected revenue [1][2] - Kingmed Diagnostics has faced significant challenges with accounts receivable, which reached 4.396 billion yuan, and the average accounts receivable turnover days exceeding 270 days, indicating that over 70% of annual sales are tied up [2][4] Group 2 - The IVD industry is collectively facing challenges, with over 70% of 60 disclosed IVD companies reporting a year-on-year revenue decline, and more than half experiencing losses or significant profit reductions [4] - The industry is experiencing increased competition due to a shift in payment policies and a tightening of hospital budgets, leading to extended payment cycles and increased accounts receivable [4][7] - Concentrated procurement initiatives in 2024 and 2025 are expected to further impact market dynamics, with successful bidders potentially gaining market share while non-bidders face intense competition [5] Group 3 - Companies in the IVD sector are exploring various strategies to navigate the current landscape, including focusing on domestic alternatives and refining niche markets to enhance customer loyalty and improve cash flow [6][8] - International expansion is also being pursued, with companies like Mindray Medical reporting that 44.75% of their revenue came from overseas in 2024, indicating a growing trend towards global market engagement [8] - The integration of AI technology is reshaping the IVD industry, enhancing diagnostic efficiency and driving precision treatment, although challenges remain in data, compliance, and commercialization [8]